Evidence map›Paper›PMID 38740174›Full record

ArticleJournal of cardiac failure2024

Unlocking Diversity in Cardiovascular Clinical Research: Lessons from the Screening for Cardiac Amyloidosis With Nuclear Imaging in a Minority Populations Study.

Abdirahman Wardhere, Dimitrios Bampatsias, Elizabeth Cohn, Denise Fine, Cinthia de Freitas, Cesia Gallegos, Stephen Helmke, Natalia Ionescu, Janvier Ivrose, Carlos Rodriguez and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of cardiac failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Abdirahman WardhereDepartment of Cardiology, Cardiac Amyloidosis Program, Columbia University Irving Medical, New York City, NY.
Dimitrios BampatsiasDepartment of Cardiology, Cardiac Amyloidosis Program, Columbia University Irving Medical, New York City, NY.
Elizabeth CohnFeinstein Institute for Medical Research/Northwell Health, Manhasset, NY.
Denise FineSection of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA.
Cinthia de FreitasYale School of Medicine, Section of Cardiovascular Medicine, New Haven, CT.
Cesia GallegosYale School of Medicine, Section of Cardiovascular Medicine, New Haven, CT.
Stephen HelmkeDepartment of Cardiology, Cardiac Amyloidosis Program, Columbia University Irving Medical, New York City, NY.
Natalia IonescuHarlem Hospital Center, New York City, NY.
Janvier IvroseHarlem Hospital Center, New York City, NY.
Carlos RodriguezDepartment of Cardiology, Cardiac Amyloidosis Program, Columbia University Irving Medical, New York City, NY.
Natalia SabogalSection of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA.
Sergylensky FilsSection of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA.
Terrence HenryHarlem Hospital Center, New York City, NY.
Sergio TeruyaDepartment of Cardiology, Cardiac Amyloidosis Program, Columbia University Irving Medical, New York City, NY.
Ikram UllahSection of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA.
Damian KurianHarlem Hospital Center, New York City, NY.
Farbod RaiszadehHarlem Hospital Center, New York City, NY.
Edward J MillerYale School of Medicine, Section of Cardiovascular Medicine, New Haven, CT.
Frederick L RubergSection of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA.
Mathew S MaurerDepartment of Cardiology, Cardiac Amyloidosis Program, Columbia University Irving Medical, New York City, NY. Electronic address: msm10@cumc.columbia.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
SCAN-MP (Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations) COVID-19 SuppplementR01HL139671 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAURER, MATHEW S, RUBERG, FREDERICK LIEF · 2019 to 2023
$7.4M
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac AmyloidosisR01AG081582 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MATHEW S MAURER · 2023 to 2026
$2.8M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL139671NIA NIH HHS R01 AG081582
6 · The paper itself

Abstract

backgroundThe Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations study seeks to determine the prevalence of transthyretin cardiac amyloidosis (ATTR-CA) among older Black or Caribbean Hispanic individuals with heart failure and an increased wall thickness. We noticed varied recruitment percentages across the recruiting sites and sought to determine the factors associated with greater percentage enrollment of eligible participants.

methodsThe percentage of enrolled to eligible participants was calculated across study sites. Baseline demographic and clinical characteristics, health literacy, trust in providers, perceived discrimination, area deprivation index (ADI) and English proficiency were compared by site using Kruskal-Wallis's test or one-way ANOVA for continuous variables and the Chi-Square test or Fisher's exact test for categorical variables. Wilcoxon rank sum and Chi-Square tests, with multiple comparisons correction using the false discovery rate (FDR) method, were used as post-hoc analysis when results were statistically significant.

resultsAmong the four recruiting sites, Boston Medical Center, Columbia University Irving Medical Center, Harlem Hospital and Yale University, which employed different recruitment approaches, the percentage of participants enrolled among eligible participants differed, with the highest rate at Harlem Hospital (n=149 of 310, 48%), followed by Yale University (n=27 of 67, 40%), Boston University (n=247 of 655, 38%), and Columbia University (n=137of 442, 32%), p <0.01. Direct recruitment by the primary cardiovascular care team providing clinical care was associated with higher percent enrolled across sites as were higher education levels and English proficiency. Enrollment differences across sites were not associated with the number of chronic diseases, physician trust, perceived discrimination, or health literacy.

conclusionsRecruitment of eligible under-represented minorities (URMs) in SCAN-MP was associated with approaches employed in recruitment, including direct initial contact by the primary cardiovascular care team providing the potential participant's clinical care. Such data may help improve approaches to more successful recruitment of URMs in clinical research.

Indexed as

CardiomyopathiesAgedAmyloid Neuropathies, FamilialBiomedical ResearchBlack or African AmericanFemaleHeart FailureHispanic or LatinoHumansMaleMass ScreeningMiddle AgedMinority GroupsPatient SelectionUnited StatesdisparitiesHeart failurerecruitment percentageSCAN-MP study

Identifiers

PMID38740174
PMCPMC11551251

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.